News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Mar 08, 2022 4:05pm EST

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022

Feb 02, 2022 7:30am EST

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Nov 09, 2021 4:05pm EST

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 01, 2021 4:05pm EDT

Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021

Oct 28, 2021 7:58am EDT

Brickell Biotech Prices Public Offering of Common Stock

Oct 27, 2021 4:32pm EDT

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

Oct 07, 2021 6:55am EDT

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Sep 17, 2021 8:00am EDT

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

Sep 08, 2021 8:30am EDT

Brickell Biotech to Participate at Upcoming September Conferences

Sep 01, 2021 7:05am EDT

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer